Swept-source OCT better for imaging posterior sclera, not lamina cribrosa

Article

Swept-source optical coherence tomography (OCT) may be superior to enhanced depth imaging (EDI)-OCT in imaging the posterior sclera, but not in imaging the lamina cribrosa, according to a study published online in the American Journal of Ophthalmology.

Swept-source optical coherence tomography (OCT) may be superior to enhanced depth imaging (EDI)-OCT in imaging the posterior sclera, but not in imaging the lamina cribrosa, according to a study published on-line in the American Journal of Ophthalmology.

Researchers from The Catholic University of Korea, Seoul, obtained both EDI-OCT and swept-source OCT images in 32 myopic patients with glaucoma. B-scan images were used to obtain subfoveal choroidal, subfoveal scleral, and central laminar thicknesses, performed at three locations by two masked observers.

With EDI-OCT, the posterior border of the sclera was visible in 31% of eyes, compared with 53% using swept-source OCT. Using McNemar's Χ2-test, detection of the posterior border of the sclera was significantly different between the two imaging modalities (P = 0.008), while that of the posterior border of the lamina cribrosa was similar. In highly myopic eyes, the detection rate of the posterior border of the sclera and lamina cribrosa was not significantly different. Intersystem intraclass correlation coefficient (ICC) was 0.769 for subfoveal scleral thickness and 0.900 for laminar thickness. Mean subfoveal scleral thickness was 464.32 μm with EDI-OCT, compared with 650.26 μm with swept-source OCT, a statistically significant difference (P = 0.018).

To view a copy of the abstract, click here.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Jeremiah Tao, MD, FACS, discusses his Egyptian Ophthalmological Society keynote, which focused on risk management and avoiding surgical complications in oculofacial surgery
Omer Trivizki, MD, MBA, a retina specialist from Tel Aviv Medical Center, speaks about VOY-101, a Novel, Complement-Modulating Gene Therapy for Geographic Atrophy at the American Society of Retina Specialists (ASRS) Annual Meeting
João Pedro Marques, MD, MSc, PhD discusses a retrospective study of 800 patients with inherited retinal diseases during the American Society of Retina Specialists (ASRS) annual meeting
© 2025 MJH Life Sciences

All rights reserved.